Matinas BioPharma Appoints New Chief Medical Officer
Ticker: MTNB · Form: 8-K · Filed: Nov 27, 2024 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Nov 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel, biotech
TL;DR
Matinas BioPharma just hired a new CMO, Dr. Terry L. Horgan. Big move for their drug development!
AI Summary
Matinas BioPharma Holdings, Inc. announced on November 27, 2024, the appointment of Dr. Terry L. Horgan as Chief Medical Officer. Dr. Horgan brings extensive experience in clinical development and medical affairs, previously holding leadership roles at companies like Merck and Pfizer.
Why It Matters
The appointment of a new Chief Medical Officer is crucial for guiding the company's clinical strategy and development pipeline, potentially impacting the future success of its drug candidates.
Risk Assessment
Risk Level: medium — The appointment of a new executive can introduce uncertainty regarding strategic direction and execution, though it also presents an opportunity for fresh leadership.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- Dr. Terry L. Horgan (person) — Appointed Chief Medical Officer
- Merck (company) — Previous employer of Dr. Horgan
- Pfizer (company) — Previous employer of Dr. Horgan
FAQ
What is the effective date of Dr. Terry L. Horgan's appointment as Chief Medical Officer?
The filing does not explicitly state an effective date for the appointment, but it was reported on November 27, 2024.
What previous companies has Dr. Terry L. Horgan worked for?
Dr. Horgan has held leadership roles at Merck and Pfizer.
What is the primary responsibility of the Chief Medical Officer at Matinas BioPharma?
The filing indicates the role involves leading clinical development and medical affairs, crucial for the company's drug pipeline.
Is Dr. Horgan's compensation package detailed in this filing?
This specific 8-K filing focuses on the appointment and does not detail Dr. Horgan's compensation arrangements.
What is Matinas BioPharma's primary business sector?
Matinas BioPharma Holdings, Inc. is in the Pharmaceutical Preparations sector, with SIC code 2834.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-11-27 17:00:19
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-24-048036.txt ( ) — 207KB
- mtnb-20241127.xsd (EX-101.SCH) — 3KB
- mtnb-20241127_lab.xml (EX-101.LAB) — 33KB
- mtnb-20241127_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: November 27, 2024 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer -3-